MPN Research gains momentum with Increased Funding The MPN Research Foundation and The Leukemia & Lymphoma Society (LLS) are proud to announce that ten new research projects will receive funding through their collaboration, renamed MPN Challenge in 2014. The focus areas for this project were conceived at a meeting of academia and industry convened by […]
Jakafi One Step Closer to Approval for Polycythemia Vera
Jakafi Improves Symptoms in PV In phase 3 randomized controlled trial, Jakafi (ruxolitinib) improved several key symptoms in polycythemia vera, according to Dr Srdan Verstovsek of MD Anderson Cancer Center in Houston. Results from the RESPONSE trial were presented at the 2014 ASCO (American Society of Clinical Oncology) annual meeting in Chicago. PV is a […]
Final of 3 MPN Patient Surveys
Update on Upcoming MPN surveys March 27, 2025 update Dear MPN Community, We are currently in an unprecedented time regarding greater understanding of myeloproliferative neoplasms (MPNs). The testing of new therapeutic agents and a genuine effort to improve the education of providers and patients will help increase options and achieve better patient outcomes. This spring […]
Patient Access Network Foundation
Financial Assistance for MPN Medications The PAN Foundation (PAN) offers assistance and hope to people with chronic or life-threatening illnesses for whom cost limits access to breakthrough medical treatments. Assistance from PAN allows patients to pay other bills, relieves stress and positively impacts overall health. I can personally attest this organization has been extremely helpful in […]
Impact of JAK-inhibitor therapy on inflammation-mediated comorbidities in MPNs
by Dr. Hans C Hasselbalch Chronic inflammation is suggested to contribute to the Philadelphia-chromosome-negative myeloproliferative neoplasm (MPN) disease initiation and progression, as well as the development of premature atherosclerosis and may drive the development of other cancers in MPNs, both nonhematologic and hematologic. The MPN population has a substantial comorbidity burden, including cerebral, cardiovascular, pulmonary, abdominal, […]
Geron’s Clinical Trials of Imetelstat put on Hold
FDA asks Geron to Halt Development of Imetelstat The FDA has placed it’s only pipeline candidate, imetelstat, on full clinical hold. The news sent shares of GERN plunging 61% on March 12, 2014. Geron had submitted an Investigation New Drug (IND) application for imetelstat, but the FDA issued a verbal notice halting the trials. This […]
Synopsis of ASH 2013 Abstract – Peginvera study
by Dr. Angela Fleischman Synopsis of ASH 2013 Abstract: “Analysis of Molecular Responses and Chromosomal Aberrations in patients with PV treated with Peg-Proline-Interferon Alpha-2b (AOP2014/P1101) in the Peginvera study” by Them et al This abstract describes the chromosomal analysis of PV patients on the Peginvera study (a study investigating a long-acting IFNa which can be […]
New Physician Based MPN Newsletter Emerges
MPN Updates – New Resource for Physicians by David Wallace As the number of MPN patients continues to grow, the need for innovative, physician-based resources has started to develop. While patient based (and Foundation/non-profit) websites focused on MPNs have flourished during the last few years, our disease tends to get tossed into the general “blood cancer” coverage, […]
Proposed Revision of WHO Diagnostic Criteria for MPNs
Synopsis of: An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for Myeloproliferative Neoplasms by Dr. Angela Fleischman We are rapidly learning more about the mutations acquired by cancer cells, this is particularly evident in blood malignancies. Most recently, calreticulin mutations have been identified in the majority of […]
PV Reporter Newsletter #5, Feb. 8, 2014
PV Reporter Update Greetings PV Reporter readers – I want to give you an update on some recent activity as we weather the winter chill. This is an exciting time, as there are many discoveries being made in the MPN world. As you may have guessed by now, I don’t send out too many newsletters […]
- « Previous Page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- …
- 21
- Next Page »